Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology ConferenceBusiness Wire • 01/12/23
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.Business Wire • 01/11/23
Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 MillionBusiness Wire • 01/10/23
Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 01/06/23
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDSBusiness Wire • 01/04/23
Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS PatientsBusiness Wire • 12/12/22
Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDSBusiness Wire • 11/03/22
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected MilestonesBusiness Wire • 11/03/22